Extremity Cryocompression Therapy for Symptom Relief in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunochemotherapy Including Carboplatin, Taxanes, and Immune Checkpoint Inhibitors - Extremity Cryocompression Therapy for Symptom Relief in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunochemotherapy Including Carboplatin, Taxanes, and Immune Checkpoint Inhibitors

Shonan Fujisawa Tokushukai Hospital, Respiratory medicine, Makoto Hibino0 sites47 target enrollmentMay 17, 2023

ConditionsSCLC

Overview

Phase: 未知
Intervention: Not specified
Conditions: SCLC
Sponsor: Shonan Fujisawa Tokushukai Hospital, Respiratory medicine, Makoto Hibino
Enrollment: 47
Status: Recruiting
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

May 17, 2023

End Date

December 31, 2026

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Shonan Fujisawa Tokushukai Hospital, Respiratory medicine, Makoto Hibino

•1\) Presence of peripheral neuropathy with self\-reported symptoms (Common Terminology Criteria for Adverse Events: CTCAE grade 2 or higher), excluding those caused by systemic conditions such as diabetes, connective tissue diseases, uremia, vitamin B1 deficiency, cervical or lumbar spondylosis, etc. Objective tests, such as nerve conduction velocity, are not mandatory for excluding peripheral neuropathy. 2\) History of Guillain\-Barre syndrome or chronic inflammatory demyelinating polyneuropathy. 3\) Presence of tumor\-related neuropathy. 4\) Presence of cognitive impairment or consciousness disturbance preventing completion of the EORTC QLQ\-CIPN20 questionnaire. 5\) Presence of open wounds or ulcers in the limbs. 6\) Severe peripheral arterial disease. 7\) Poorly controlled diabetes (HbA1c \> 8\.0%) at screening. 8\) History of Raynaud's phenomenon. 9\) Intolerance to cold. 10\) Other reasons determined by the principal investigator that render the patient unsuitable for inclusion in the study.